DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2005/0203190 A1 Burgard Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2005/0203190 A1 Burgard Et Al US 20050203190A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2005/0203190 A1 Burgard et al. (43) Pub. Date: Sep. 15, 2005 (54) METHODS OF TREATING Related U.S. Application Data GASTRONTESTINAL TRACT DISORDERS USING SODIUM CHANNEL MODULATORS (62) Division of application No. 10/769,071, filed on Jan. 30, 2004. (75) Inventors: Edward C. Burgard, Chapel Hill, NC (US); Steven B. Landau, Wellesley, (60) Provisional application No. 60/443,731, filed on Jan. MA (US); Matthew Oliver Fraser, 30, 2003. Provisional application No. 60/443,730, Apex, NC (US) filed on Jan. 30, 2003. Provisional application No. 60/480,565, filed on Jun. 20, 2003. Provisional appli cation No. 60/480,598, filed on Jun. 20, 2003. Pro Correspondence Address: visional application No. 60/495,958, filed on Aug. 18, ALSTON & BIRD LLP 2003. BANK OF AMERICA PLAZA 101 SOUTH TRYON STREET, SUITE 4000 Publication Classification CHARLOTTE, NC 28280-4000 (US) (51) Int. Cl. ............................................ A61K 31/137 (52) U.S. Cl. .............................................................. 514/649 (73) ASSignee: Dynogen Pharmaceuticals, Inc., Waltham, MA (57) ABSTRACT The invention relates to methods of using Sodium channel (21) Appl. No.: 11/057,024 modulators, particularly TTX-R sodium channel modulators and/or activity dependent Sodium channel modulators to treat a gastrointestinal tract disorders, particularly inflam (22) Filed: Feb. 11, 2005 matory bowel disorders and irritable bowel syndrome. Patent Application Publication Sep.15, 2005 Sheet 1 of 2 US 2005/0203190 A1 Figure 1. A. lamotrigine Control Control 26A750pA fastslow 5ms slow fast 100 s to 80 is 60 s 5(9 40 5 a S. 20 control slow 100M slow control fast 100M fast Patent Application Publication Sep.15, 2005 Sheet 2 of 2 US 2005/0203190 A1 Figure 2. A. N 1oom ambroxo --- N-ul-M1 2nA 2 secs B. 100 80 60 40 20 M ambroxol US 2005/0203190 A1 Sep. 15, 2005 METHODS OF TREATING GASTRONTESTINAL except when very Severe, is limited to the bowel mucosa. TRACT DISORDERS USING SODIUM CHANNEL The course of this disorder may be continuous or relapsing MODULATORS and may be mild or Severe. Medical treatment primarily includes the use of Salicylate derivatives, glucocorticoster CROSS-REFERENCE TO RELATED oids Such as prednisone or prednisone acetate and anti APPLICATIONS metabolites dependent on the clinical State of the patient. Salicylate derivatives, Such as Sulphazine or meSalamine, are 0001. This application is a divisional of copending U.S. efficacious in patients with mild cases of the disorder. application Ser. No. 10/769,071, filed Jan. 30, 2004; which Glucocorticosteroids and anti-metabolites are efficacious in claims the benefit of U.S. Provisional Application No. patients with moderate or Severe disease but are associated 60/443,731, filed Jan. 30, 2003, U.S. Provisional Applica with a number of side effects. Patients who need chronic tion No. 60/443,730, filed Jan. 30, 2003, U.S. Provisional doses of glucocorticosteroids or anti-metabolites for control Application No. 60/480,565, filed Jun. 20, 2003, U.S. Pro of their disorder eventually undergo removal of the colon visional Application No. 60/480,598, filed Jun. 20, 2003, Surgically to eliminate the disease. and U.S. Provisional Application No. 60/495,958, filed Aug. 18, 2003; the contents of which are herein incorporated by 0007 Like ulcerative colitis, Crohn's disease (also reference in their entirety. known as regional enteritis, ileitis, or granulomatous ileo colitis) is a chronic inflammatory disorder of unknown FIELD OF THE INVENTION etiology; however the location and pathology of the disease differ. Crohn's disease typically presents in either the Small 0002 The invention relates to methods of using sodium intestine, large intestine or the combination of the two channel modulators, particularly TTX-R sodium channel locationsand can cause inflammation deeper into the muscle modulators and/or activity dependent Sodium channel and serosa located within the intestinal wall. The course of modulators, to treat gastrointestinal tract disorders, particu the disorder may be continuous or relapsing and may be mild larly inflammatory bowel disorders and irritable bowel syn or Severe. Medical treatment includes the continuous use of drome. Salicylate derivatives, glucocorticosteroids, anti-metabo lites, and administration of an anti-TNF antibody. Many BACKGROUND OF THE INVENTION Crohn's disease patients require intestinal Surgery for a 0003 Gastrointestinal (GI) tract disorders affect the qual problem related to the disease, but unlike ulcerative colitis ity of life of millions of men and women in the United States Subsequent relapse is common. every year. GI tract disorders may involve disturbances of 0008 Collagenous colitis and lymphocytic colitis are the GI Smooth muscle, epithelium, Sensory afferent neurons, idiopathic inflammatory disorders of the colon that cause or central nervous System pathways. In Spite of the uncer watery diarrhea typically in middle-aged or older individu tainty regarding whether central or peripheral mechanisms, als. Lymphocytic colitis is distinguished from collagenous or both, are involved in GI tract disorders, many proposed colitis by the absence of a thickened Subepithelial collag mechanisms implicate neurons and pathways that mediate enous layer. Bismuth in the form of Pepto-Bismol may be an Visceral Sensation. Viscerosensory information from the GI effective treatment in Some patients, although more Severe tract is relayed by Sensory fibers that enter the Spinal cord via cases may require the use of Salicylate derivatives, antibi the dorsal root ganglion (DRG) or project to the nodose otics Such as metronidazole, and glucocorticosteroids. ganglion via Vagal afferents (Physiology, ed. R. M. Berne and M. N. Levy, 1983, CV Mosby Co. St. Louis). A number of 0009 Functional GI tract disorders are characterized by different Subtypes of Sensory afferent neurons may be presentation of abdominal-type Symptoms without evidence involved in neurotransmission from the GI tract. These may of changes in metabolism or Structural abnormalities. Dis be classified as, but not limited to, Small diameter, medium orders that are typically considered under functional disor diameter, large diameter, myelinated, unmyelinated, Sacral, ders include dysphagia, non-ulcer dyspepsia, irritable bowel lumbar, DRG, Vagal, nodose, peptidergic, non-peptidergic, Syndrome, Slow-transit constipation, and evacuation disor IB4 positive, IB4 negative, C fiber, Aö fiber, AB fiber, high ders (Camilleri (2002) Gastrointestinal Motility Disorders, threshold or low threshold neurons. In WebMDScientific American Medicine, edited by David C. Dale and Daniel D. Federman, New York, N.Y., WebMD). A 0004 GI tract disorders have been characterized as struc prominent example of a functional GI tract disorder is tural (or mucosal) GI tract disorders and non-structural (or irritable bowel syndrome (IBS), also known by a variety of non-mucosal) GI tract disorders. Structural disorders include Synonyms, including functional bowel, pylorospasm, ner inflammatory bowel disorders and non-inflammatory Struc Vous indigestion, Spastic colon, Spastic colitis, Spastic tural GI tract disorders. Non-structural disorders include a bowel, intestinal neurosis, functional colitis, irritable colon, variety of disorders classified as functional GI tract disor mucous colitis, laxative colitis, and functional dyspepsia. derS. IBS generally leads to abdominal pain and/or discomfort and 0005 Inflammatory bowel disorders include a group of an alteration in bowel habit with no clear etiology. Diagnosis disorders that can cause inflammation or ulceration of the GI relies on Rome criteria taking into account all Symptoms tract. Ulcerative colitis and Crohn's disease are the most related to patient presentation. (See, e.g., Drossman et al. common types of inflammatory bowel disorders, although (1997) Gastroenterology, 112. 2120). Patients typically collagenous colitis, lymphocytic (microscopic) colitis, and present with Symptoms consistent with hyperalgesia and other disorders have also been described. allodynia. 0006 Ulcerative colitis is a chronic inflammatory disor 0010. At present, treatments for IBS have been largely der of unknown etiology afflicting the large intestine and, ineffective, and have included StreSS management, diet, and US 2005/0203190 A1 Sep. 15, 2005 drugs. Psychoactive drugs, Such as anxiolytics and antide Diverticulosis is a disorder that rarely occurs in the Small preSSants, have been utilized but have limited utility because intestine and most commonly appears in the colon. of the Side effect profile. Antispasmodics and various antidi 0014. Because existing therapies and treatments for GI arrheal preparations have also been used but these remain as tract disorders are associated with limitations as described unsatisfactory remedies to patients with IBS. above, new therapies and treatments are therefore desirable. 0011 Non-ulcer dyspepsia (NUD) is another prominent example of a functional GI tract disorder with no established SUMMARY OF THE INVENTION etiology. Symptoms related to NUD include nausea, vom 0015 Compositions and methods for treating GI tract iting, pain, early Satiety, bloating and loSS of appetite. disorders, particularly inflammatory bowel disorders and Altered gastric emptying and increased gastric Sensitivity irritable bowel syndrome, are provided. Compositions of the and distress may contribute to NUD but do not completely
Load more

Recommended publications
  • TARIF DES DOUANES - ANNEXE 99 - I
    TARIF DES DOUANES - ANNEXE 99 - i Chapitre 99 DISPOSITIONS DE CLASSIFICATION SPÉCIALE - COMMERCIALES Notes. 1. Les dispositions du présent Chapitre ne sont pas régies par la règle de spécificité de la Règle générale interprétative 3 a). 2. Les marchandises qui peuvent être classées dans les dispositions du Chapitre 99, sont classées dans le Chapitre 98 si elles peuvent également être classées dans ce chapitre. 3. Les marchandises peuvent être classées dans un numéro tarifaire du présent Chapitre et peuvent bénéficier des taux de droits de douane du tarif de la nation la plus favorisée ou du tarif de préférence prévus au présent Chapitre qui s’appliquent à ces marchandises selon le traitement tarifaire applicable selon le pays d’origine, mais ce classement est subordonné au classement préalable de celles-ci dans un numéro tarifaire des Chapitres 1 à 97 et à l’observation des conditions prévues par les textes d’application qui leurs sont applicables. 4. Les termes utilisés dans ce Chapitre et dans les Chapitres 1 à 97 s’entendent au sens de ces derniers Chapitres. Émis 1 janvier 2018 99 - 1 TARIF DES DOUANES - ANNEXE Numéro Unité Tarif de la Tarif de préférence SS Dénomination des marchandises tarifaire de mes. N.P.F. applicable 9901.00.00 Articles et matières devant servir à la fabrication ou à la réparation des En fr. TPAC, TPMD, TPG, produits suivants devant être utilisés dans la pêche commerciale ou TÉU, TM, TMÉU, TACI, dans la récolte commerciale de plantes aquatiques : TC, TCR, TI, TN, TSL, TP, TCOL, TJ, TPA, Appâts artificiels; TNH, TKR, TCUE, TUA : En fr.
    [Show full text]
  • Poisons and Narcotic Drugs (Amendment) Ordinance 1988
    AUSTRALIAN CAPITAL TERRITORY Poisons and Narcotic Drugs (Amendment) Ordinance 1988 No. 96 of 1988 I, THE GOVERNOR-GENERAL of the Commonwealth of Australia, acting with the advice of the Federal Executive Council, hereby make the following Ordinance under the Seat of Government (Administration) Act 1910. Dated 15 December 1988 N. M. STEPHEN Governor-General By His Excellency’s Command, CLYDE HOLDING Minister of State for the Arts and Territories An Ordinance to amend the Poisons and Narcotic Drugs Ordinance 1978 Short title 1. This Ordinance may be cited as the Poisons and Narcotic Drugs (Amendment) Ordinance 1988.1 Commencement 2. This Ordinance commences on such date as is fixed by the Minister by notice in the Gazette. Principal Ordinance 3. In this Ordinance, “Principal Ordinance” means the Poisons and Narcotic Drugs Ordinance 1978.2 (Ord. 79/88)—Cat. No. Authorised by the ACT Parliamentary Counsel—also accessible at www.legislation.act.gov.au 2 Poisons and Narcotic Drugs (Amendment) No. 96, 1988 Substances to which Division applies 4. Section 27B of the Principal Ordinance is amended by adding at the end the following paragraphs: “; (f) follicle stimulating hormone; (g) luteinising hormone; (h) thalidomide.”. Grant of authorisation 5. Section 27E of the Principal Ordinance is amended— (a) by omitting from paragraph (1) (a) “or cyclofenil” and substituting “, cyclofenil, follicle stimulating hormone or luteinising hormone”; (b) by omitting from paragraph (1) (b) “and”; and (c) by adding at the end of subsection (1) the following word and paragraph: “; and (d) in the case of an application that relates to thalidomide— the applicant is a specialist physician with no less than 5 years’ experience in the treatment of erythema nodosum leprosum.”.
    [Show full text]
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
    [Show full text]
  • The Role of Antispasmodics in Managing Irritable Bowel Syndrome
    DOI: https://doi.org/10.22516/25007440.309 Review articles The role of antispasmodics in managing irritable bowel syndrome Valeria Atenea Costa Barney,1* Alan Felipe Ovalle Hernández.1 1 Internal Medicine and Gastroenterology specialist Abstract in San Ignacio University Hospital, Pontificia Universidad Javeriana, Bogotá, Colombia. Although antispasmodics are the cornerstone of treating irritable bowel syndrome, there are a number of an- tispasmodic medications currently available in Colombia. Since they are frequently used to treat this disease, *Correspondence: [email protected] we consider an evaluation of them to be important. ......................................... Received: 26/10/18 Keywords Accepted: 11/02/19 Antispasmodic, irritable bowel syndrome, pinaverium bromide, otilonium bromide, Mebeverin, trimebutine. INTRODUCTION consistency. The criteria must be met for three consecutive months prior to diagnosis and symptoms must have started Irritable bowel syndrome (IBS) is one of the most fre- a minimum of six months before diagnosis. (3, 4) quent chronic gastrointestinal functional disorders. It is There are no known structural or anatomical explanations characterized by recurrent abdominal pain associated with of the pathophysiology of IBS and its exact cause remains changes in the rhythm of bowel movements with either or unknown. Nevertheless, several mechanisms have been both constipation and diarrhea. Swelling and bloating are proposed. Altered gastrointestinal motility may contribute frequent occurrences. (1) to changes in bowel habits reported by some patients, and a IBS is divided into two subtypes: predominance of cons- combination of smooth muscle spasms, visceral hypersen- tipation (20-30% of patients) and predominance of dia- sitivity and abnormalities of central pain processing may rrhea (20-30% of patients).
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1
    Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • Pharmacy and Poisons Act 1979
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS ACT 1979 1979 : 26 TABLE OF CONTENTS PART I PRELIMINARY 1 Short title 2 Interpretation PART II THE PHARMACY COUNCIL 3 The Pharmacy Council 4 Membership of the Council 4A Functions of the Council 4B Protection from personal liability 4C Annual Report 5 Proceedings of the Council, etc PART III REGISTRATION OF PHARMACISTS 6 Offence to practise pharmacy if not registered 7 Registration as a pharmacist 7A Re-registration as non-practising member 7AA Period of validity of registration 8 Code of Conduct 9 Pharmacy Profession Complaints Committee 10 Investigation of complaint by Committee 10A Inquiry into complaint by Council 10B Inquiry by Council of its own initiative 11 Surrender of registration 12 Restoration of name to register 1 PHARMACY AND POISONS ACT 1979 13 Proof of registration 14 Appeals 14A Fees 14B Amendment of Seventh Schedule 15 Regulations for this part PART IV REGISTRATION OF PHARMACIES 16 Register of pharmacies 17 Registration of premises as registered pharmacies 18 Unfit premises: new applications 19 Unfit premises: registered pharmacies 20 Appeals 21 When certificates of unfitness take effect 22 Regulations for this Part PART V CONTROL OF PRESCRIPTIONS AND IMPORTATION 23 Prescriptions to be in a certain form 23A Validity of a prescription 24 Supply by registered pharmacist of equivalent medicines 25 Restrictions on the importation of medicines 26 Declaration relating to imported medicines [repealed] PART VI CONTROL OF DRUGS 27 Certain substances to be sold on prescription
    [Show full text]
  • A Four-Country Comparison of Healthcare Systems, Implementation
    Neurogastroenterology & Motility Neurogastroenterol Motil (2014) 26, 1368–1385 doi: 10.1111/nmo.12402 REVIEW ARTICLE A four-country comparison of healthcare systems, implementation of diagnostic criteria, and treatment availability for functional gastrointestinal disorders A report of the Rome Foundation Working Team on cross-cultural, multinational research M. SCHMULSON,* E. CORAZZIARI,† U. C. GHOSHAL,‡ S.-J. MYUNG,§ C. D. GERSON,¶ E. M. M. QUIGLEY,** K.-A. GWEE†† & A. D. SPERBER‡‡ *Laboratorio de Hıgado, Pancreas y Motilidad (HIPAM)-Department of Experimental Medicine, Faculty of Medicine-Universidad Nacional Autonoma de Mexico (UNAM). Hospital General de Mexico, Mexico City, Mexico †Gastroenterologia A, Department of Internal Medicine and Medical Specialties, University La Sapienza, Rome, Italy ‡Department of Gastroenterology, Sanjay Gandhi Postgraduate Institute of Medical Science, Lucknow, India §Department of Gastroenterology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea ¶Division of Gastroenterology, Mount Sinai School of Medicine, New York, NY, USA **Division of Gastroenterology and Hepatology, Houston Methodist Hospital and Weill Cornell Medical College, Houston, TX, USA ††Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore ‡‡Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel Key Messages • This report identified seven key issues related to healthcare provision that may impact how patients with FGIDs are investigated, diagnosed and managed. • Variations in healthcare provision around the world in patients with FGIDs have not been reviewed. • We compared four countries that are geographically and culturally diverse, and exhibit differences in the healthcare coverage provided to their population: Italy, South Korea, India and Mexico. • Since there is a paucity of publications relating to the issues covered in this report, some of the findings are based on the authors’ personal perspectives, press reports and other published sources.
    [Show full text]
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
    WHO/PSM/QSM/2006.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Medicines Policy and Standards The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • (19) 11 Patent Number: 6165500
    USOO6165500A United States Patent (19) 11 Patent Number: 6,165,500 Cevc (45) Date of Patent: *Dec. 26, 2000 54 PREPARATION FOR THE APPLICATION OF WO 88/07362 10/1988 WIPO. AGENTS IN MINI-DROPLETS OTHER PUBLICATIONS 75 Inventor: Gregor Cevc, Heimstetten, Germany V.M. Knepp et al., “Controlled Drug Release from a Novel Liposomal Delivery System. II. Transdermal Delivery Char 73 Assignee: Idea AG, Munich, Germany acteristics” on Journal of Controlled Release 12(1990) Mar., No. 1, Amsterdam, NL, pp. 25–30. (Exhibit A). * Notice: This patent issued on a continued pros- C.E. Price, “A Review of the Factors Influencing the Pen ecution application filed under 37 CFR etration of Pesticides Through Plant Leaves” on I.C.I. Ltd., 1.53(d), and is subject to the twenty year Plant Protection Division, Jealott's Hill Research Station, patent term provisions of 35 U.S.C. Bracknell, Berkshire RG12 6EY, U.K., pp. 237-252. 154(a)(2). (Exhibit B). K. Karzel and R.K. Liedtke, “Mechanismen Transkutaner This patent is Subject to a terminal dis- Resorption” on Grandlagen/Basics, pp. 1487–1491. (Exhibit claimer. C). Michael Mezei, “Liposomes as a Skin Drug Delivery Sys 21 Appl. No.: 07/844,664 tem” 1985 Elsevier Science Publishers B.V. (Biomedical Division), pp 345-358. (Exhibit E). 22 Filed: Apr. 8, 1992 Adrienn Gesztes and Michael Mazei, “Topical Anesthesia of 30 Foreign Application Priority Data the Skin by Liposome-Encapsulated Tetracaine” on Anesth Analg 1988; 67: pp 1079–81. (Exhibit F). Aug. 24, 1990 DE) Germany ............................... 40 26834 Harish M. Patel, "Liposomes as a Controlled-Release Sys Aug.
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]